New heart valve implant offers hope for congenital heart patients
NCT ID NCT03110861
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a new valve called the Pulsta® Transcatheter Pulmonary Valve in 15 people with congenital heart disease and a faulty pulmonary valve. The valve is implanted through a catheter, avoiding open-heart surgery. Researchers checked if the valve improved blood flow and was safe to use over 6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pulsta® Transcatheter Pulmonary Valve (a replacement heart valve implanted through a catheter)
What this could lead to
If successful, this valve could offer a less invasive option for people with congenital heart disease who need a new pulmonary valve, potentially avoiding open-heart surgery.
What could go wrong
This was a small early study with only 15 people, so results may not apply to everyone. As with any implant, there are risks of complications like valve leakage or device-related serious events.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY VALVE STENOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, Olympic-ro, Songpa-gu, 05505, South Korea
-
Samsung Medical Center
Seoul, Ilwon-ro, Gangnam-gu, 06351, South Korea
-
Sejong General Hospital
Bucheon-si, Hohyun-ro, Sosa-gu, 14754, South Korea
-
Seoul National University Hospital
Seoul, Haehak-ro Jongno-gu, 03080, South Korea
-
Severance Hospital
Seoul, Yonsei-ro, Seodaemun-gu, 03722, South Korea